Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 5.

Müller, Julian; Ferraro, Daniela A; Muehlematter, Urs J; Garcia Schüler, Helena I; Kedzia, Sarah; Eberli, Daniel; Guckenberger, Matthias; Kroeze, Stephanie G C; Sulser, Tullio; Schmid, Daniel M; Omlin, Aurelius; Müller, Alexander; Zilli, Thomas; John, Hubert; Kranzbuehler, Helmut; Kaufmann, Philipp A; von Schulthess, Gustav K; Burger, Irene A (2019). Clinical impact of 68Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction. European Journal of Nuclear Medicine and Molecular Imaging, 46(4):889-900.

Omlin, Aurelius; Spahn, Martin; Beyer, Jörg; Eberli, Daniel; Gillessen, Silke; Jochum, Wolfram; Kueng, Marc; Nitzsche, Egbert; Rentsch, Cyrill A; Roggero, Enrico; Schmid, Hans-Peter; Stenner, Frank; Templeton, Arnoud J; Wild, Damian; Wyler, Stephen; Zwahlen, Daniel; Cathomas, Richard (2018). Behandlung des fortgeschrittenen Prostatakarzinoms – eine interdisziplinäre Empfehlung. Praxis, 107(19):1043-1051.

Fankhauser, Christian D; Schüffler, Peter J; Gillessen, Silke; Omlin, Aurelius; Rupp, Niels J; Rueschoff, Jan H; Hermanns, Thomas; Poyet, Cedric; Sulser, Tullio; Moch, Holger; Wild, Peter J (2018). Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer. OncoTarget, 9(12):10284-10293.

Omlin, Aurelius; Blum, David; Wierecky, Jan; Haile, Sarah R; Ottery, Faith D; Strasser, Florian (2013). Nutrition impact symptoms in advanced cancer patients: frequency and specific interventions, a case-control study. Journal of Cachexia, Sarcopenia and Muscle, 4(1):55-61.

Laurent, Julien; Touvrey, Cedric; Gillessen, Silke; Joffraud, Magali; Vicari, Manuela; Bertrand, Caroline; Ongarello, Stefano; Liedert, Bernd; Gallerani, Elisa; Beck, Joachim; Omlin, Aurelius; Sessa, Cristiana; Quaratino, Sonia; Stupp, Roger; Gnad-Vogt, Ulrike S; Speiser, Daniel E (2013). T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein. Journal of Translational Medicine, 11:5.

This list was generated on Sun Jun 16 19:12:11 2019 CEST.